The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRBS.L Regulatory News (RBS)

  • There is currently no data for RBS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Additional provision for US RMBS investigations

26 Jan 2017 07:00

RNS Number : 1779V
Royal Bank of Scotland Group PLC
26 January 2017
 

The Royal Bank of Scotland Group plc

Additional provision for US RMBS investigations and litigation

 

26 January 2017

 

 

The Royal Bank of Scotland Group plc (together with its subsidiaries, "RBS") will announce its Full Year 2016 results on 24 February 2017. Subject to any increase being required by intervening developments, the Q4 2016 results will reflect the taking of a further £3.1bn ($3.8bn) provision in relation to various investigations and litigation matters relating to RBS's issuance and underwriting of US residential mortgage-backed securities ("RMBS"). This takes the total aggregate of such provisions to £6.7bn ($8.3bn) as at 31 December 2016. This further provision would have reduced RBS's Tangible Net Asset Value ("TNAV") per share at 30 September 2016 by 27p to 311p and RBS's Q3 2016 CET1 capital ratio by 135bps to 13.6%. This provision does not directly impact the distributable reserves of The Royal Bank of Scotland Group plc.

 

RBS continues to cooperate with the US Department of Justice ("DOJ") in its civil and criminal investigations of RMBS matters, and RBS considers it appropriate to take this provision now in relation to those investigations as well as other RMBS litigation matters. The duration and outcome of these investigations and other RMBS litigation matters remain uncertain, including in respect of whether settlements for all or any of such matters may be reached.

 

RBS emphasises that further substantial additional provisions and costs may be recognised and, depending on the final outcome, other adverse consequences may occur (see RBS's existing market disclosures). The existing disclosures also provide further details of the US RMBS-related investigations by the DOJ and other agencies and bodies, including several state attorneys general, and various litigation matters.

 

Ross McEwan, RBS's Chief Executive Officer, said:

 

"Putting our legacy litigation issues behind us, including those relating to RMBS, remains a key part of our strategy. It is our priority to seek the best outcome for our shareholders, customers and employees."

 

Ross McEwan (Chief Executive Officer) and Ewen Stevenson (Chief Financial Officer) will host a conference call for investors and analysts at 8.00am UK time today. A replay of the call will be made available shortly afterwards. Only items relating to the above announcement will be discussed on the call; there will be no references and discussion relating to other matters and the Full Year 2016 results. Dial-in details for the call can be found below.

 

Dial-in details:

UK: 0800 694 8082

International: +44 (0) 1452 568 172

US: +1 866 966 8024

Conference ID: 60246489

 

Replay details:

UK FreeCall: 0800 953 1533

Std International: +44 (0)1452 550 000

USA FreeCall: +1 (866) 247 4222

Conference ID: 60246489

 

 

For further information, please contact:

 

Investor Relations

Alexander Holcroft

Head of Equity Investor Relations

+44 (0) 20 7672 1758

 

Matthew Richardson

Head of Fixed Income Investor Relations

+44 (0) 20 7678 1800

 

RBS Media Relations

+44 (0) 131 523 4205

 

Forward Looking Statements

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those related to RBS and its subsidiaries' regulatory capital position, risk-weighted assets, impairment losses and credit exposures under certain specified scenarios. In addition, forward-looking statements may include, without limitation, statements typically containing words such as "intends", "expects", "anticipates", "targets", "plans", "estimates" and words of similar import. These statements concern or may affect future matters, such as RBS's future economic results, business and capital plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties that might cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statements. Factors that could cause or contribute to differences in current expectations include, but are not limited to, legislative, fiscal and regulatory developments, competitive conditions, technological developments, exchange rate fluctuations and general economic conditions. These and other factors, risks and uncertainties that may impact any forward-looking statement or RBS's actual results are discussed in RBS's UK Annual Report and materials filed with, or furnished to, the US Securities and Exchange Commission, including, but not limited to, RBS's Reports on Form 6-K and most recent Annual Report on Form 20-F. The forward-looking statements contained in this announcement speak only as of the date of this announcement and RBS does not assume or undertake any obligation or responsibility to update any of the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.

 

Legal Entity Identifier: 2138005O9XJIJN4JPN90

 

ENDS

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQQLBLDFFZBBX
Date   Source Headline
17th Apr 201911:20 amRNSSegmental Reporting Restatement Document
1st Apr 20194:30 pmRNSDirector/PDMR Shareholding
29th Mar 20195:04 pmRNSTotal Voting Rights
27th Mar 20192:05 pmRNSPublication of Final Terms
20th Mar 201910:17 amRNSRBSG pricing of US$2 billion of Senior Notes
19th Mar 20198:30 amRNSMorgan Stanley European Financials Conference
13th Mar 20196:26 pmRNSNotice of Redemption
11th Mar 20193:00 pmRNSDirector/PDMR Shareholding
7th Mar 20194:56 pmRNSForm 8.3 - Findel plc
6th Mar 20192:45 pmRNSForm 8.3 - MedicX Fund Limited
1st Mar 20191:10 pmRNSForm 8.3 - MedicX Fund Limited
1st Mar 201912:01 pmRNSDirector/PDMR Shareholding
1st Mar 20197:00 amRNSFiling of Annual Report on Form 20-F with US SEC
28th Feb 20192:25 pmRNSDividend Declaration
28th Feb 201912:40 pmRNSTotal Voting Rights
26th Feb 20195:50 pmRNSPublication of Supplementary Prospectus
22nd Feb 201912:51 pmRNSUpdate on NatWest Markets transfer scheme
22nd Feb 201912:00 pmRNSDirector/PDMR Shareholding
15th Feb 20193:00 pmRNSPublication of Supplementary Prospectus
15th Feb 20197:02 amRNSDirectorate Change
15th Feb 20197:01 amRNSAnnual Financial Report
15th Feb 20197:00 amRNSFinal Results
6th Feb 20194:16 pmRNSResult of Meeting
6th Feb 20192:55 pmRNSGM Statement
31st Jan 201911:42 amRNSTotal Voting Rights
29th Jan 20192:55 pmRNSDirector/PDMR Shareholding
25th Jan 20191:27 pmRNSForm 8.3 Disclosure
17th Jan 20194:10 pmRNSNotice of GM
9th Jan 20195:02 pmRNSHolding(s) in Company
31st Dec 20181:13 pmRNSTotal Voting Rights
28th Dec 20184:28 pmRNSDirector/PDMR Shareholding
27th Dec 20184:55 pmRNSDividend Declaration
18th Dec 20183:55 pmRNSDirectorate Change
14th Dec 20186:15 pmRNSRBS welcome credit ratings action by Fitch Ratings
14th Dec 20183:33 pmRNSPublication of a Prospectus
6th Dec 20184:40 pmRNSSecond Price Monitoring Extn
6th Dec 20184:35 pmRNSPrice Monitoring Extension
6th Dec 20182:16 pmRNSNatWest Markets transfer scheme
30th Nov 20182:30 pmRNSTotal Voting Rights
30th Nov 20181:12 pmRNSDirector/PDMR Shareholding
29th Nov 20184:28 pmRNSDividend Declaration
29th Nov 20184:07 pmRNSNotice of Redemption
29th Nov 201811:34 amRNSNotice of Rdemption
29th Nov 201811:33 amRNSNotice of Redemption
29th Nov 201811:31 amRNSNotice of Redemption
29th Nov 201811:31 amRNSNotice of Redemption
29th Nov 20188:00 amRNSRBS Investor Seminar: Commercial Banking
28th Nov 20185:09 pmRNS2018 Bank of England stress test results
16th Nov 201812:00 pmRNSDirector/PDMR Shareholding
9th Nov 20184:16 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.